SCHEMBL3560692

SCHEMBL3560692

CC(=O)/C=C/c1ccc(C(F)(F)F)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 1/20 0.51
PTGS1 P23219 1/20 0.51
APP P05067 6/20 0.48
GLA P06280 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
FDPS P14324 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP1A1 P04798 1/20 0.40
CYP1B1 Q16678 1/20 0.40
BACE1 P56817 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2B6 P20813 1/20 0.39
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
HDAC3 O15379 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560696 1.00 IAPP (0.51) IAPPPTGS1APPGLATDP1
SCHEMBL3894458 0.86 APP (0.47) APPCYP1A2CYP1A1CYP1B1BACE1
SCHEMBL6030726 0.86 APP (0.47) APPCYP1A2CYP1A1CYP1B1BACE1
SCHEMBL6030455 0.83 APP (0.55) APPFDPSPOLBPKMKDM4E
SCHEMBL6030457 0.83 APP (0.55) APPFDPSPOLBPKMKDM4E
SCHEMBL1404873 0.81 IAPP (0.65) IAPPPTGS1APPGLATDP1
SCHEMBL16141410 0.81 IAPP (0.51) IAPPPTGS1APPGLATDP1
SCHEMBL1404874 0.81 IAPP (0.65) IAPPPTGS1APPGLATDP1
SCHEMBL3559966 0.80 APP (0.64) APPFDPSCYP1A2POLBPKM
SCHEMBL3559970 0.80 APP (0.64) APPFDPSCYP1A2POLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001849-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-11-26 EP disclosed
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 IAPP 3436/4885PTGS1 1583/4885APP 1165/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 IAPP 3612/4885PTGS1 693/4885APP 1511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.